No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 122 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma September 8, 2023 Cancer Research UK appoints new Trustees and independent Committee Members March 16, 2023 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 Load more HOT NEWS COVID-19 Testing: What you need to know. How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? Lion With Skin Cancer Has Received Radiation Therapy In Hospital Why haven’t we cured cancer? – That Cancer Conversation
